Download PDF
Horm Metab Res 2010; 42(1): 8-13
DOI: 10.1055/s-0029-1237728
Original Basic

© Georg Thieme Verlag KG Stuttgart · New York

Oral Glucose Tolerance Test Effects on Endothelial Inflammation Markers in Healthy Subjects and Diabetic Patients

G. Derosa1 , A. D’Angelo1 , S. A. T. Salvadeo1 , I. Ferrari1 , E. Fogari1 , A. Gravina1 , R. Mereu1 , I. Palumbo1 , P. Maffioli1 , S. Randazzo1 , A. F. G. Cicero2
  • 1Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
  • 2“G. Descovich” Atherosclerosis Study Center, “D. Campanacci” Clinical Medicine and Applied Biotechnology Department, University of Bologna, Bologna, Italy
Further Information

Publication History

received 17.04.2009

accepted 05.08.2009

Publication Date:
04 September 2009 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of this study was to evaluate the effect of an oral glucose tolerance test (OGTT) on the level of endothelial dysfunction and vascular inflammation markers in healthy subjects (H) and diabetic overweight patients (D). We enrolled 256 healthy subjects and 274 type 2 diabetic patients. We evaluated blood glucose (BG), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), high-sensitivity C reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), and tumor necrosis factor-α (TNF-α) at baseline and after OGTT. We observed that BG, sICAM-1, IL-6, hs-CRP, sVCAM-1, sE-selectin, and TNF-α values were higher in D group than in H group. In a large sample of adult healthy subjects and type 2 diabetics we observed that both answer to an OGTT with a significant increase in biomarkers of systemic low-grade inflammation and endothelial dysfunction such as hsCRP, IL-6, TNF-α, sICAM-1, sVCAM-1, and sE-selectin. Type 2 diabetics experienced, however, a more significant increase in TNF-α, and sE-selectin.

Key words

type 2 diabetes mellitus - soluble adhesion molecules - vessels dysfunction - cardiovascular risk

References

  • 1 Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: targets and interventions.  Diabetes Care. 2008;  31 ((Suppl 2)) S215-S221
    Google Scholar
  • 2 Bartnik M, Norhammar A, Rydén L. Hyperglycaemia and cardiovascular disease.  J Intern Med. 2007;  262 145-156
    Google Scholar
  • 3 Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.  Diabetes Care. 2008;  31 ((Suppl 2)) S155-S160
    Google Scholar
  • 4 Asadollahi K, Beeching N, Gill G. Hyperglycaemia and mortality.  J R Soc Med. 2007;  100 503-507
    Google Scholar
  • 5 Bell DS, O’Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?.  Endocr Pract. 2008;  14 112-124
    Google Scholar
  • 6 Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose – a review of diagnosis, clinical implications and management.  Diab Vasc Dis Res. 2005;  2 9-15
    Google Scholar
  • 7 American Diabetes Association. . Screening for diabetes (Position Statement).  Diabetes Care. 2001;  24 S21-S24
    Google Scholar
  • 8 World Health Organization. .Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity. Geneva: WHO June 1997
  • 9 European Diabetes Policy Group. . A desktop guide to type 2 diabetes mellitus.  Diab Med. 1999;  16 716-730
    Google Scholar
  • 10 Song M, Kellum JA. Interleukin-6.  Crit Care Med. 2005;  33 S463-465
    Google Scholar
  • 11 Zhang M, Tracey K. The Cytokine Handbook. 3rd ed. San Diego: Academic Press 1988
  • 12 Rifai N, Tracy RP, Ridker PM. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay.  Clin Chem. 1999;  45 2136-2141
    Google Scholar
  • 13 Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview.  Eur Cytokine Netw. 2004;  15 91-98
    Google Scholar
  • 14 Peter K, Weirich U, Nordt TK, Ruef J, Bode C. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis.  Thromb Haemost. 1999;  82 38-43
    Google Scholar
  • 15 Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease.  Clin Chim Acta. 2006;  368 33-47
    Google Scholar
  • 16 American Diabetes Association. . Standards of Medical Care in Diabetes.  Diabetes Care. 2007;  30 S4-S41
    Google Scholar
  • 17 Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York: McGraw-Hill 1971
  • 18 Matthews JNS, Altman DG, Campbell MJ, Royton P. Analysis of serial measurements in medical research.  BMJ. 1990;  300 230-235
    Google Scholar
  • 19 Tanabe N, Saito K, Yamada Y, Takasawa T, Seki N, Suzuki H. Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes.  Intern Med. 2009;  48 401-409
    Google Scholar
  • 20 Ferri C, Desideri G, Baldoncini R, Bellini C, De Angelis C, Mazzocchi C, Santucci A. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities.  Diabetes. 1998;  47 660-667
    Google Scholar
  • 21 Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. High serum concentrations of soluble E-selectin in patients with impaired glucose tolerance with hyperinsulinemia.  Atherosclerosis. 2000;  152 415-420
    Google Scholar
  • 22 Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes.  Diabetologia. 2002;  45 210-216
    Google Scholar
  • 23 Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro.  Diabetes. 1996;  45 954-959
    Google Scholar
  • 24 Ruotsalainen E, Vauhkonen I, Salmenniemi U, Pihlajamäki J, Punnonen K, Kainulainen S, Jalkanen S, Salmi M, Laakso M. Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects.  Atherosclerosis. 2008;  197 271-277
    Google Scholar
  • 25 Kowalska I, Straczkowski M, Szelachowska M, Kinalska I, Prokop J, Bachórzewska-Gajewska H, Stepien A. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism.  Metabolism. 2002;  51 733-736
    Google Scholar
  • 26 Morohoshi M, Fujisawa K, Uchimura I, Numano F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes.  Ann N Y Acad Sci. 1995;  748 562-570
    Google Scholar
  • 27 Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes.  J Clin Endocrinol Metab. 2000;  85 2970-2973
    Google Scholar
  • 28 Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, Esposito K, Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.  Circulation. 2005;  111 2518-2524
    Google Scholar
  • 29 Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, Chaudhuri A, Dandona P. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects.  Metabolism. 2006;  55 1177-1185
    Google Scholar
  • 30 Dhindsa S, Tripathy D, Mohanty P, Ghanim H, Syed T, Aljada A, Dandona P. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells.  Metabolism. 2004;  53 330-334
    Google Scholar
  • 31 Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment.  Diabetes. 2004;  53 701-710
    Google Scholar
  • 32 Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress.  Circulation. 2002;  106 2067-2072
    Google Scholar
  • 33 Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.  J Am Coll Cardiol. 2002;  39 1145-1150
    Google Scholar
  • 34 Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb U. Inflammation in Metabolic Syndrome and Type 2 Diabetes. Impact of Dietary Glucose.  Ann N Y Acad Sci. 2006;  1084 30-48
    Google Scholar
  • 35 Derosa G, D’Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.  Intern Med. 2007;  46 1837-1846
    Google Scholar
  • 36 Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.  Clin Ther. 2004;  26 744-754
    Google Scholar
  • 37 LeRoith D. Treatment of diabetes: a clinical update on insulin trials.  Clin Cornerstone. 2007;  8 2129
    Google Scholar
  • 38 Derosa G, Fogari E, Cicero AF, D’Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.  Hypertens Res. 2007;  30 387394
    Google Scholar
  • 39 Bogdanski P, Pupek-Musialik D, Dytfeld J, Jagodzinski PP, Jablecka A, Kujawa A, Musialik K. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus.  Int J Clin Pharmacol Ther. 2007;  45 563-567
    Google Scholar

Correspondence

G. DerosaMD, PhD 

Department of Internal Medicine and Therapeutics University of Pavia

Fondazione IRCCS Policlinico S. Matteo

P. le C. Golgi 2

27100 Pavia

Italy

Phone: +39/0382/52 62 17

Fax: +39/0382/52 62 59

Email: giuseppe.derosa@unipv.it